期刊
EXPERT OPINION ON EMERGING DRUGS
卷 14, 期 1, 页码 67-84出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728210902769601
关键词
clinical trials; neurogenesis; neuroprotection; neurorestoration; pharmacological; traumatic brain injury
资金
- NINDS [PO1 NS23393, PO1 NS42345, RO1 NS42259, RO1 NS062002]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS023393, R01NS062002, R01NS042259, P01NS042345] Funding Source: NIH RePORTER
Background: This review summarizes promising approaches for the treatment of traumatic brain injury (TBI) that are in either preclinical or clinical trials. Objective: The pathophysiology underlying neurological deficits after TBI is described. An overview of select therapies for TBI with neuroprotective and neurorestorative effects is presented. Methods: A literature review of preclinical TBI studies and clinical TBI trials related to neuroprotective and neurorestorative therapeutic approaches is provided. Results/conclusion: Nearly all Phase II/III clinical trials in neuroprotection have failed to show any consistent improvement in outcome for TBI patients. The next decade will witness an increasing number of clinical trials that seek to translate preclinical research discoveries to the clinic. Promising drug- or cell-based therapeutic approaches include erythropoietin and its carbamylated form, statins, bone marrow stromal cells, stem cells singularly or in combination or with biomaterials to reduce brain injury via neuroprotection and promote brain remodeling via angiogenesis, neurogenesis, and synaptogenesis with a final goal to improve functional outcome of TBI patients. In addition, enriched environment and voluntary physical exercise show promise in promoting functional outcome after TBI, and should be evaluated alone or in combination with other treatments as therapeutic approaches for TBI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据